JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. (JCRRF) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for JCR Pharmaceuticals Co., Ltd. (JCRRF), featuring income statements, balance sheets, and cash flow data.
JCR Pharmaceuticals Co., Ltd. (JCRRF) Income Statement & Financial Overview
Explore comprehensive income reports for JCR Pharmaceuticals Co., Ltd. JCRRF, broken down by year and quarter.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $7.19B | $9.22B | $8.51B | $8.14B |
| Cost of Revenue | $4.37B | $2.68B | $2.26B | $2.29B |
| Gross Profit | $2.82B | $6.55B | $6.37B | $5.86B |
| Gross Profit Ratio | $0.39 | $0.71 | $0.75 | $0.72 |
| R&D Expenses | $5.51B | $3.35B | $3.40B | $0.00 |
| SG&A Expenses | $3.26B | $3.21B | $3.30B | $6.37B |
| Operating Expenses | $8.76B | $6.56B | $6.70B | $6.37B |
| Total Costs & Expenses | $13.14B | $9.24B | $8.96B | $8.65B |
| Interest Income | $22.00M | $0.00 | $41.00M | $27.00M |
| Interest Expense | $52.00M | $0.00 | $37.00M | $26.00M |
| Depreciation & Amortization | $868.00M | $799.25M | $841.00M | $826.00M |
| EBITDA | -$5.18B | $739.25M | -$47.00M | $1.22B |
| EBITDA Ratio | -$0.72 | $0.08 | -$0.006 | $0.15 |
| Operating Income | -$5.94B | -$15.00M | -$443.00M | -$510.00M |
| Operating Income Ratio | -$0.83 | -$0.002 | -$0.05 | -$0.06 |
| Other Income/Expenses (Net) | -$153.00M | $253.00M | -$482.00M | $73.00M |
| Income Before Tax | -$6.10B | $238.00M | -$925.00M | $369.00M |
| Income Before Tax Ratio | -$0.85 | $0.03 | -$0.11 | $0.05 |
| Income Tax Expense | -$1.88B | $36.00M | -$40.00M | $164.00M |
| Net Income | -$4.18B | $115.00M | -$891.00M | $201.00M |
| Net Income Ratio | -$0.58 | $0.01 | -$0.10 | $0.02 |
| EPS | -$33.80 | $0.93 | -$7.15 | $1.61 |
| Diluted EPS | -$33.80 | $0.94 | -$7.15 | $1.61 |
| Weighted Avg Shares Outstanding | $123.74M | $123.25M | $124.83M | $124.81M |
| Weighted Avg Shares Outstanding (Diluted) | $123.74M | $121.82M | $124.83M | $124.84M |
Over the last four quarters, JCR Pharmaceuticals Co., Ltd.'s revenue moved from $8.14B in Q1 2025 to $7.19B in Q4 2025. Operating income in Q4 2025 was -$5.94B, with a strong operating margin of -83%. Despite fluctuations in R&D and SG&A expenses, EBITDA for JCR Pharmaceuticals Co., Ltd. remained robust at -$5.18B, reflecting operational efficiency. Net income dropped to -$4.18B, with an EPS of -$33.80. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan